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Introduction: Amrubicin is a promising agent in the treatment of
lung cancer, but predictive biomarkers have not yet been described.
NAD(P)H:quinone oxidoreductase 1 (NQO1) is an enzyme known
to metabolize amrubicinol, the active metabolite of amrubicin, to an
inactive compound. We examined the relationship between NQO1
and amrubicinol cytotoxicity.
Methods: Gene and protein expression of NQO1, amrubicinol
cytotoxicity, and C609T single-nucleotide polymorphism of NQO1
were evaluated in 29 lung cancer cell lines: 14 small cell lung cancer
(SCLC) and 15 non-SCLC (NSCLC). The involvement of NQO1 in
amrubicinol cytotoxicity was evaluated by small interfering RNA
against NQO1.
Results: A significant inverse relationship between both gene and
protein expression of NQO1 and amrubicinol cytotoxicity was found in
all cell lines. Treatment with NQO1 small interfering RNA increased
amrubicinol cytotoxicity and decreased NQO1 expression in both
NSCLC and SCLC cells. Furthermore, cell lines genotyped homozy-
gous for the 609T allele showed significantly lower NQO1 protein
expression and higher sensitivity for amrubicinol than those with the
other genotypes in both NSCLC and SCLC cells.
Conclusions: NQO1 expression is one of the major determinants for
amrubicinol cytotoxicity, and C609T single-nucleotide polymor-
phism of NQO1 could be a predictive biomarker for response to
amrubicin treatment.
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Amrubicin, a totally synthetic 9-aminoanthracycline anti-cancer drug, is approved in Japan for the treatment of
lung cancer. A phase II study of amrubicin showed overall
response rates (ORRs) of more than 75% and approxi-
mately 20% in patients with previously untreated small
cell lung cancer (SCLC) and non-SCLC (NSCLC), respec-
tively.1,2 Recently, amrubicin treatment has been recog-
nized to be an active and well-tolerated regimen in patients
with previously treated SCLC3,4 and NSCLC.5 Amrubicin
has worldwide potential for patients with lung cancer, but
predictive biomarkers for the activity of this agent have yet
to be elucidated.6
In general, anthracyclines are inactivated following
conversion to the C-13 hydroxy metabolite by carbonyl
reductase (CBR).7 As with other anthracyclines, amrubicin
is reduced to its C-13 hydroxy metabolite, amrubicinol;
uniquely, the cytotoxicity of amrubicinol in vitro is 10 to
100 times greater than that of amrubicin.8 Thus, the anti-
cancer activity of amrubicin is considered to derive from
this active metabolite.9
NAD(P)H:quinone oxidoreductase 1 (NQO1) is a cy-
tosolic flavoprotein that catalyzes the two-electron reduction
of a variety of substrates. This ubiquitous enzyme is impli-
cated in processes such as oxidant stress and carcinogenesis
and is overexpressed in many tumor tissues compared with
normal tissue.10 Amrubicin and amrubicinol contain quinone
groups, and NQO1 is known to be one of the main enzymes
that metabolize such structures.11 Thus, it seems likely that
NQO1 expression in cancer cells affects the activity of
amrubicinol, but little is known so far about the specific role
of NQO1 in amrubicinol cytotoxicity.
In this study, we examined the relationship between
gene and protein expression level of NQO1 and amrubicinol
cytotoxicity using lung cancer cell lines and evaluated the
effect on amrubicinol cytotoxicity of small interfering RNA
(siRNA) against NQO1 to assess the involvement of NQO1
expression in amrubicinol cytotoxicity. Moreover, the
C609T single-nucleotide polymorphism (SNP) of the
NQO1 gene is associated with a loss of enzyme activity
because of instability of the protein product.12,13 There-
fore, we also examined the relationship between genotype
of C609T SNP and amrubicinol cytotoxicity to evaluate
this SNP’s potential use as a predictive marker of amru-
bicin cytotoxicity.
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MATERIALS AND METHODS
Cell Lines and Chemicals
The following 29 human lung cancer cell lines were used
in this study: 14 SCLC cell lines (PC-6, SBC3, DMS53, NCI-
H69, NCI-H417, NCI-H1688, SK-LC-17, SK-LC-2, ACC-
LC-5, ACC-LC-48, ACC-LC-67, ACC-LC-73, ACC-LC-80,
and ACC-LC-172), 10 adenocarcinoma cell lines (PC-9, A549,
NCI-H23, SK-LC-1, ACC-LC-94, ACC-LC-174, ACC-LC-
314, RERF-LC-MS, RERF-LC-MT, and RERF-LC-OK), 3
squamous cell carcinoma cell lines (PC-1, PC-10, and QG56),
and 2 large cell carcinoma cell lines (NCI-H460 and SK-LC-6).
PC-6 was kindly provided by Daiichi Pharmaceutical (Tokyo,
Japan), and the other cell lines were provided by Aichi Cancer
Center or purchased from the American Type Culture Collec-
tion. Cells were cultured in Roswell Park Memorial Institute
medium 1640 supplemented with 10% heat-inactivated fetal
bovine serum and 1% (vol/wt) penicillin/streptomycin, and the
medium was changed every 4 to 7 days. Amrubicinol was
provided by Nihon Kayaku (Tokyo, Japan).
Chemosensitivity Assay
Cells were cultured at 5000 cells/well in a 96-well
tissue culture plate. To assess cell viability, stepwise dilutions
of amrubicinol were added 2 hours after plating. After
72 hours, MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt
solution) (CellTiter 96 AQueous One Solution Cell Proliferation
Assay, Promega, Madison, WI) was added, and the cells were
incubated for a further 4 hours, after which the absorbance was
measured at 490 nm using an enzyme-linked immunosorbent
assay plate reader. The experiment was performed in triplicate.
Chemosensitivity was expressed as the drug concentration for
50% cell survival (IC50), as determined from the concentration–
effect relationship using GraphPad Prism version 4 (GraphPad
Software, San Diego, CA).
Total RNA Extraction and Quantitative Real-
Time Reverse-Transcriptase Polymerase Chain
Reaction
Total RNA was extracted using the RNeasy Mini Kit
(Qiagen, Hilden, Germany). Quantitative real-time reverse-tran-
scriptase polymerase chain reaction (RT-PCR) was performed in
a volume of 20 l with the Taqman One-Step RT-PCR Master
Mix Reagents Kit (Applied Biosystems, Foster City, CA) using
the StepOnePlus Real-Time PCR System (Applied Biosystems)
according to the manufacturer’s recommendations. The cycling
conditions were as described previously.14 The experiment was
performed in triplicate. The primer and Taqman probe sets
(Taqman Gene Expression Assays, Inventoried) for NQO1
(Hs00168547_m1), NADPH:cytochrome P-450 reductase
(POR) (Hs00287016_m1) and glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) (Hs99999905_m1) were purchased
from Applied Biosystems (sequences not disclosed). Expression
was normalized to the housekeeping gene GAPDH.
Protein Extraction and Western Blotting
Equal amounts of total cell lysates were solubilized in
the sample buffer (50 mmol/liter Tris–HCL [pH 6.8], 2%
SDS, 1 mmol/liter ethylenediaminetetraacetic acid, and 10%
glycerol) with Complete Mini; Protease Inhibitor Cocktail
Tablets; and Phos-STOP Phosphatase Inhibitor Cocktail
(Roche Applied Science, Indianapolis, IN). Subsequently,
these lysates were electrophoresed on 10% Ready Gel Tris–
HCl Gel (Bio-Rad Laboratories, Hercules, CA) and trans-
ferred to Immobilon-P membrane (Millipore, Billerica, MA).
The membrane was incubated with either a primary antibody
to NQO1 (1:5000, ab28947; Abcam, Cambridge, UK) or
-tubulin (1:10,000, T6199; Sigma-Aldrich Corporation,
Saint Louis, MO) for 1 hour. After washing in a Tris-buffered
saline solution of Tween-20, the protein was visualized using
the ECL detection kit (GE Healthcare, Munich, Germany)
with a peroxidase-labeled antimouse antibody (1:25,000,
NIF825; GE Healthcare). Protein expression of NQO1 was
determined relative to -tubulin, and relative band intensities
were determined by densitometry using NIH Image.
Modification of Amrubicinol Cytotoxicity by
RNA Interference
Approximately 2  105 cells were plated in six-well
plates in Roswell Park Memorial Institute medium 1640
supplemented with 10% heat-inactivated fetal bovine serum.
After 24 hours, the cells were transfected with two types of
siRNA oligonucleotide for NQO1 or negative control siRNA
(siCtrol) using siPORT NeoFX Transfection Agent (Ambion,
Austin, TX) to give a final RNA concentration of 10 nmol/
liter, according to the manufacturer’s instructions. Total RNA
and protein were extracted 24 and 72 hours after transfection,
respectively. To assess sensitivity to amrubicinol, the me-
dium was changed, and the cells were seeded at 5000 cells/
well in 96-well tissue culture plates 24 hours after being
transfected. Stepwise dilutions of amrubicinol were added 2
hours after plating. After 48 hours, MTS solution was added,
and then after 4 hours, the absorbance was measured at 490
nm using an enzyme-linked immunosorbent assay plate
reader. The two types of siRNA oligonucleotide for NQO1
(predesigned siRNA, ID s4090 and s4091) and the negative
siCtrol were purchased from Ambion.
Genomic DNA Extraction and Detection of
SNP in the NQO1 Gene
Genomic DNA was extracted from the 29 aforemen-
tioned lung cancer cell lines using the QIAamp DNA Mini
Kit (Qiagen) according to the manufacturer’s instructions.
The C609T SNP of the NQO1 gene was detected using the
StepOnePlus Real-Time PCR System (Applied Biosystems)
and Taqman Drug Metabolism Genotyping Assays (Applied
Biosystems), according to the manufacturer’s instructions.
The primer and Taqman probe set for the SNP were pur-
chased from Applied Biosystems. The assay ID of the SNP
was C_2091255_30.
Statistical Analysis
Statistical analysis was performed using Student’s t
test. The correlation between gene/protein expression levels
and IC50 values for amrubicinol was evaluated by Spear-
man’s test.
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RESULTS
NQO1 Expression and Amrubicinol
Cytotoxicity in Lung Cancer Cells
NQO1 and POR, which is also known as P450R, are the
main enzymes that metabolize amrubicinol.11 To assess the
involvement of these enzymes in amrubicinol sensitivity, we
examined the relationship between gene expression levels of
these enzymes and the IC50 values for amrubicinol in 29 lung
cancer cell lines. We found that gene expression of NQO1
correlated significantly with amrubicinol IC50 values (Figure
1A), whereas POR did not (Figure 1B).
Relationship Between Protein Expression of
NQO1 and Amrubicinol Cytotoxicity
The catalytic activity of NQO1 is correlated with
NQO1 protein expression,15 so we also evaluated the rela-
tionship between protein expression of NQO1 and amrubi-
cinol cytotoxicity in lung cancer cells: NQO1 protein expres-
sion levels and IC50 values for each cell line are shown in
Table 1. As shown in Figure 2A, a significant correlation
between expression of NQO1 and amrubicinol IC50 was
found. The mean value of IC50 for amrubicinol and the mean
value of NQO1 protein expression were both significantly
higher in NSCLC cell lines than in SCLC cell lines (Figures
2B, C).
Alteration of Amrubicinol Cytotoxicity by
NQO1 siRNA
To confirm the involvement of NQO1 in amrubicinol
cytotoxicity, we examined the effect of siRNA against
NQO1. We used NCI-H460 and NCI-N417 cells, because
these cell lines have relatively high NQO1 protein expression
(Table 1), and transfected two types of siRNA oligonucleo-
tides for NQO1 (siNQO1–1, siNQO1–2) and negative siCtrol.
NQO1 gene expression in NCI-H460 cells transfected with
the siRNAs against NQO1 was significantly lower than in
cells transfected with negative siCtrol (Figure 3A), and pro-
tein expression in these cells was also confirmed to be lower
(Figure 3B). Furthermore, the cytotoxicity of amrubicinol in
NCI-H460 cells transfected with siRNA against NQO1 was
significantly higher than in those transfected with negative
siCtrol (Figure 3C). Similar results were observed in
NCI-N417 cells (Figures 3D–F).
FIGURE 1. Relationship between expression lev-
els of NAD(P)H:quinone oxidoreductase 1 (NQO1)
and NADPH:cytochrome P-450 reductase (POR)
genes and amrubicinol sensitivity in lung cancer
cell lines. A, Relationship between gene expression
levels of NQO1 and drug concentration for 50%
cell survival (IC50) values. B, Relationship between
gene expression levels of POR and IC50 values.
Statistical significances of the correlations were
determined by Spearman’s test.


















PC-6 Sm 14.7 0.65 C/T PC-9 Ad 580.4 2.44 C/C
SBC3 Sm 128.7 0.56 C/T A549 Ad 2221 1.67 C/C
DMS53 Sm 201.1 0.79 C/C NCI-H23 Ad 40.5 1.11 C/C
NCI-H69 Sm 146.0 0.42 T/T SK-LC-1 Ad 702.6 2.35 C/C
NCI-N417 Sm 790.0 1.46 C/C ACC-LC-94 Ad 183.6 0.19 T/T
NCI-H1688 Sm 208.8 0.93 C/C ACC-LC-174 Ad 591.7 0.24 T/T
SK-LC-17 Sm 352.7 0.51 C/C ACC-LC-314 Ad 2842 4.03 C/T
SK-LC-2 Sm 207.8 0.12 C/C RERF-LC-MS Ad 98.6 0.44 T/T
ACC-LC-5 Sm 27.6 0.12 T/T RERF-LC-MT Ad 96.1 1.81 C/C
ACC-LC-48 Sm 46.5 0.19 C/T RERF-LC-OK Ad 173.9 1.37 C/C
ACC-LC-67 Sm 108.1 0.23 T/T PC-1 Sq 1884 2.26 C/T
ACC-LC-73 Sm 124.5 0.26 C/C PC-10 Sq 739.2 0.87 C/T
ACC-LC-80 Sm 416.3 1.42 C/C QG56 Sq 923.9 0.94 C/T
ACC-LC-172 Sm 7.3 0.13 T/T NCI-H460 Lar 3550 2.19 C/C
SK-LC-6 Lar 202.2 0.34 C/C
Sm, small cell carcinoma; Ad, adenocarcinoma; Sq, squamous cell carcinoma; Lar, large cell carcinoma; IC50, fifty percent cell survival; NQO1, NAD(P)H:quinone
oxidoreductase 1.
a Relative ratio compared with -tubulin expression.
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Relationship Between Genotype of C609T SNP
and Amrubicinol Cytotoxicity
The NQO1 gene has previously been reported to have
functional SNPs: the C609T SNP of NQO1 is associated with
protein expression.12 We examined genotypes of this SNP in
the 29 lung cancer cell lines. Western blots for NQO1 protein
and C609T genotypes in representative NSCLC cell lines are
shown in Figure 4A. NQO1 expression in cell lines genotyped
homozygous for minor alleles (T/T, lanes 3–5) was relatively
low compared with those cell lines genotyped homozygous
for major alleles (C/C, lanes 6–9) or heterozygous (C/T, lanes
1 and 2). Next, we compared quantitative protein expression
FIGURE 2. Relationship between expression levels of NAD(P)H:quinone oxidoreductase 1 (NQO1) protein and amrubicinol
sensitivity in lung cancer cell lines. A, Relationship between expression levels of NQO1 protein and drug concentration for
50% cell survival (IC50). Statistical significances of the correlations were determined by Spearman’s test. Open circle, small-cell
lung cancer (SCLC) cell lines. Closed circle, non-SCLC (NSCLC) cell lines. B, The IC50 values for amrubicinol in SCLC and
NSCLC cell lines. Each mean value is compared statistically. *p less than 0.05. C, NQO1 protein expression values in SCLC and
NSCLC cell lines. Each mean value is compared statistically. **p less than 0.01.
FIGURE 3. Inhibition of NAD(P)H:quinone oxidoreductase 1 (NQO1) expression and alteration of cytotoxicity to amrubicinol
by siRNA. NCI-H460 and NCI-N417 cells were transfected with two types of small interfering RNA (siRNA) directed against
NQO1 (siNQO1-1 and siNQO1-2) or negative control siRNA (siCtrol). A, D, NQO1 gene expression levels in cells transfected
with each siRNA and nontransfected cells (A, NCI-H460; D, NCI-N417). Data are presented as percentages based on the value
in nontransfected cells. Each value of siNQO1-1 and siNQO1-2 is statistically compared with the value of siCtrol. *p less than
0.05 and **p less than 0.01. B, E, NQO1 protein expression in cells transfected with each siRNA and nontransfected cells by
Western blotting (B, NCI-H460; E, NCI-N417). -tubulin was used as loading control. C, F, Cytotoxicity to amrubicinol in cells
transfected with each siRNA and nontransfected cells (C, NCI-H460; F, NCI-N417). Each value of siNQO1-1 and siNQO1-2 is
statistically compared with the value in siCtrol. Each point represents the mean  SD of four independent measurements. *p
less than 0.05, **p less than 0.01, and ***p less than 0.001.
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in cell lines genotyped T/T and those genotyped C/C or C/T.
As shown in Figure 4B, the mean NQO1 protein expression
level in NSCLC cell lines genotyped T/T was significantly
lower than in those genotyped C/C or C/T. Furthermore, the
mean IC50 value for amrubicinol in NSCLC cell lines geno-
typed T/T was significantly lower than in NSCLC cell lines
genotyped C/C or C/T (Figure 4C). Clinically, Cmax of
amrubicinol in patients treated with amrubicin at the standard
dose of 40 mg/m2 is equivalent to 650 nmol/liter.16 IC50 was
higher than this in 10 of the 15 NSCLC cell lines, but all 3
cell lines genotyped T/T had a lower IC50 value (Table 1). In
the SCLC cell lines, the mean NQO1 protein expression level
in cell lines genotyped T/T was significantly lower than in
cell lines genotyped C/C or C/T (Figure 4D). Further, the
mean IC50 for amrubicinol was also significantly lower in cell
lines genotyped T/T than in those genotyped C/C or C/T
(Figure 4E). All SCLC cell lines except NCI-N417 had IC50
lower than 650 nmol/liter, and all cell lines genotyped T/T
were included in this lower group (Table 1).
DISCUSSION
We have demonstrated that expression of NQO1 has a
significant inverse correlation with in vitro amrubicinol cy-
totoxicity and that inhibition of NQO1 expression increases
amrubicinol cytotoxicity. These findings indicate that the
level of NQO1 expression in cancer cells is predictive of
amrubicinol cytotoxicity. Furthermore, amrubicinol sensitiv-
ity was higher in cell lines genotyped T/T for C609T SNP of
NQO1 than the other genotypes. This suggests that this SNP
could be useful as a biomarker for predicting response to
amrubicin treatment.
Amrubicin has previously been reported to show more
potent antitumor activity than doxorubicin in several human
tumor xenografts implanted in nude mice, despite its lower in
vitro cytotoxicity.8,17 In vivo anticancer activity of amrubicin
is closely related to the area under the concentration curve of
amrubicinol,9 the cytotoxicity of which is 10 to 100 times
greater than that of amrubicin in vitro8 and which has superior
selective distribution in tumor to doxorubicin.18 Thus, the
superior cytotoxicity of amrubicin is a result of amrubicinol
activity. NQO1 metabolizes amrubicinol to the inactive me-
tabolite deoxyaglycone,11 the in vitro cytotoxicity of which is
36 to 107 times lower than amrubicinol.8 NQO1 is expressed
at high levels throughout many solid tumors,10 and the activ-
ities of some bioreductive drugs, such as mitomycin C and
EO9, have been reported to be correlated with NQO1 activity
in tumor cells.19 Thus, NQO1 could be a key enzyme affect-
ing amrubicin activity in tumor cells.
NSCLC is known to show NQO1 overexpression,
whereas NQO1 activity and expression has been reported to
be lower in SCLC.20,21 We have confirmed this difference in
vitro (Figure 2C). Amrubicin shows promising efficacy in
both SCLC (ORR 75%1) and NSCLC (ORR 20%2), but the
response rates are quite different: high expression of NQO1
in NSCLC may be a reason for the difference. Furthermore,
we found a significant relationship between the level of
NQO1 protein expression and amrubicinol cytotoxicity (Fig-
ure 2A) and confirmed that inhibition of NQO1 expression by
FIGURE 4. Relationship between amrubicinol sensitivity and genotype of C609T nucleotide polymorphism (SNP) of NAD-
(P)H:quinone oxidoreductase 1 (NQO1). A, Representative NQO1 protein expression in each genotype of C609T SNP. 1; QG56,
2; PC-10, 3; ACC-LC-94, 4; ACC-LC-174, 5; RERF-LC-MS, 6; NCI-H23, 7; PC-9, 8; A549, 9; NCI-H460. B, NQO1 protein ex-
pression in non-small cell lung cancer (NSCLC) cell lines genotyped T/T, and C/C or C/T. Each mean value is compared statis-
tically. *p less than 0.05. C, Drug concentration for 50% cell survival (IC50) for amrubicinol in NSCLC cell lines genotyped T/T,
and C/C or C/T. Each mean value is compared statistically. *p less than 0.05. D, NQO1 protein expression level in small cell
lung cancer (SCLC) cell lines genotyped T/T, and C/C or C/T. Each mean value is compared statistically. *p less than 0.05. E,
Mean IC50 value for amrubicinol in SCLC cell lines genotyped T/T, and C/C or C/T. Each mean value is compared statistically.
*p less than 0.05.
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transfection of siRNA against NQO1 increased amrubicinol
cytotoxicity. These findings indicate that NQO1 expression
levels in cancer cells are a major determinant of amrubicinol
cytotoxicity.
The mechanism of regulation of NQO1 expression
remains uncertain. The transcription factor nuclear factor
erythroid-2-related factor 2 (Nrf2) mediates gene induction of
protective phase-2 detoxifying enzymes including NQO1.22
Recently, Solis et al.23 reported that increased Nrf2 expres-
sion is common abnormality in NSCLC patient specimens.
We examined the relationship between Nrf2 and NQO1
expression in lung cancer cell lines, but found no significant
relationship (data not shown). On the other hand, C609T SNP
of NQO1 results in a proline to serine substitution and
ubiquitination with rapid degradation of the variant protein.24
This SNP has been associated with an increased risk of
cancer, particularly leukemia,25,26 and was previously re-
ported as a prognostic and predictive marker following adju-
vant chemotherapy with epirubicin in breast cancer.27 Fur-
thermore, the incidence of this SNP variant varies by race and
has been observed at 5% in whites and 20% in Asians.28 The
response rate to amrubicin treatment of white SCLC patients4
was reported to be lower than that in a similar study in
Japanese patients.3,29 On the basis of these findings, we
focused on the relationship between this SNP and amrubi-
cinol cytotoxicity and found that cell lines genotyped T/T had
significantly lower NQO1 expression and more sensitivity to
amrubicinol than other genotyped cell lines in both NSCLC
and SCLC (Figure 4B–D). Further, IC50 was higher than 650
nmol/liter, which is equivalent to the amrubicinol clinical
Cmax value, in many NSCLC cell lines16: IC50 values of all
NSCLC cell lines genotyped T/T were lower than that value.
This finding supports this SNP’s potential as a biomarker to
predict the efficacy of amrubicin treatment in patients with
NSCLC. On the other hand, because the IC50 values of almost
all SCLC cell lines were lower than that value, this SNP may
select super responders to amrubicin treatment in SCLC.
We have demonstrated the role of NQO1 in amrubi-
cinol activity in vitro, but POR is another enzyme that is
known to metabolize amrubicinol to an inactive metabolite.11
In mitomycin C activation, NQO1 plays a role under both
aerobic and hypoxic conditions, whereas POR is the key
enzyme under hypoxic conditions.30,31 We found no relation-
ship between POR gene expression level and amrubicinol
cytotoxicity (Figure 1B), but further studies are needed to
assess the activities of these enzymes dependent on microenvi-
ronment. In addition, CBR is a key enzyme that metabolizes
amrubicin to amrubicinol.11 Noguchi et al.9 reported the amru-
bicinol level in tumors is lower after administration of amrubi-
cinol than that after administration of amrubicin in mice study,
which suggests that metabolism of amrubicin to amrubicinol
occurs in the tumor, so our future studies will include assessment
of the role of CBR in amrubicin cytotoxicity.
Amrubicin is highly active and is one of the potent
anticancer drugs against lung cancer. In this study, we have
demonstrated the important role of NQO1 in determining the
in vitro activity of amrubicinol and showed that C609T SNP
of NQO1 could be a predictive biomarker for response to
amrubicin treatment. Further clinical studies are warranted to
examine the significance of NQO1 in amrubicin treatment.
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